F. Amin, M. Asghar, JW Ravneberg
Feb 21, 2013
Citations
2
Influential Citations
35
Citations
Quality indicators
Journal
The Journal of Headache and Pain
Abstract
The triptans, serotonin receptor B/D agonists, are the mainstay in the acute treatment of migraine[1]. Sumatriptan, the first triptan, was originally developed as a cranial vasoconstrictor by acting on the 5-HT1B/1D receptors in cephalic vessels[2]. However, several modes of action as well as multiple sites of action have been proposed.[3]